Position Associate Professor
Telephone 041 234 8910
E-mail flavio.rizzolio@unive.it
Website www.unive.it/persone/flavio.rizzolio (personal record)
Office Department of Molecular Sciences and Nanosystems
Sito web struttura: http://www.unive.it/dep.dsmn
Where: Campus scientifico via Torino
Room: office 711 (Alfa building, 7th floor) / research lab 5 (Gamma building, ground floor)
Office European Center for Living Technology (ECLT)
Where: Ca' Bottacin
Research Institute Research Institute for Complexity

Dr. Rizzolio is an associate professor in the Department of Molecular Sciences and Nanosystems at Ca' Foscari University. He obtained the specialization in Applied Genetics in 2004 at University of Pavia. During the period 2007- 2011, he worked at the Department of Biology of Temple University (Philadelphia, USA) as a Visiting Research Scholar. During this time, he completed the PhD program in oncology and genetics. On 1 February 2011, he received the title of Assistant Professor at Temple University.

The research activity of Dr. Rizzolio can be summarized in three periods.  First phase (2000-2007): his scientific career began in 2000 with the thesis focused on the molecular and genetic analysis of two genes mapped on chromosome X candidate Premature ovarian failure (POF). It was also studied the effects of the interaction of the X and autosome chromosomes on the expression of flanking genes in POF patients with X-autosome balanced translocation. During this scientific period, he improved many basic techniques of molecular biology and genetics. Second stage (2007-2011): during the PhD program, he studied the role of many proteins involved in cell cycle control of cancer cells. In particular, it has been investigated the role of Retinoblastoma family of proteins and Pin1. During this scientific step, he improved many basic techniques of molecular/cellular biology and animal models. Third phase (2011-2016): Development of biocompatible nanodrugs in oncology. At the Centro di Riferimento Oncologico and now at Ca' Foscari University, he is working on the development of new nanodrugs based on biocompatible materials (DNA, Liposomes, exosomes).   He published more than 80 research papers and he is a member of the Editorial Advisory Board of the following journals: Nanomedicine & Nanoscience Research and Frontiers in Nanoscience.   He is the founder and CEO of BioFuture Medicine.